Published in Haematologica on April 01, 2001
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia (2006) 5.64
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Clinical outcome of extramedullary plasmacytoma. Haematologica (2000) 3.27
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst (1998) 2.96
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica (2010) 2.46
The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol (1998) 2.44
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis (2006) 2.24
Guidelines for the use of recombinant human erythropoietin. Haematologica (1995) 1.94
Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica (1997) 1.88
Cryoglobulins. J Clin Pathol (2002) 1.85
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol (1995) 1.77
Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. J Am Coll Cardiol (1999) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67
Granulocytic sarcoma with breast and skin presentation: a report of a case successfully treated by local radiation and systemic chemotherapy. Acta Haematol (2000) 1.66
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol (1998) 1.64
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol (2009) 1.62
All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: a possible disease association. Haematologica (1996) 1.61
Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood (1996) 1.59
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (2009) 1.58
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol (1996) 1.54
The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol (1999) 1.54
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia (2010) 1.54
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49
Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol (1995) 1.49
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol (1998) 1.48
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica (1997) 1.47
Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Br J Haematol (2000) 1.46
Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas. Br J Haematol (1997) 1.45
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res (2010) 1.40
A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica (1999) 1.39
Challenging paradigms in lymphoma treatment. Ann Oncol (2004) 1.39
In situ staining of bromodeoxyuridine positive cells in normal and neoplastic colony-forming units grown on plasma clots. J Immunol Methods (1988) 1.38
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol (1985) 1.30
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia (2007) 1.30
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol (1999) 1.29
A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol (2009) 1.29
Midterm clinical and angiographic results of radial artery grafts used for myocardial revascularization. J Thorac Cardiovasc Surg (1998) 1.27
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol (1999) 1.27
Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol (1997) 1.26
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol (2009) 1.20
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant (2010) 1.19
Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. J Pathol (2006) 1.19
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol (2000) 1.18
Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program (2001) 1.16
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol (2008) 1.16
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol (2006) 1.16
Staging and prognosis in chronic myelogenous leukemia. Semin Hematol (1988) 1.15
Increase in T gamma lymphocytes in B-cell chronic lymphocytic leukaemia. II. Correlation with clinical stage and findings in B-prolymphocytic leukaemia. Br J Haematol (1981) 1.15
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia (2006) 1.15
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol (2008) 1.14
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia (2007) 1.13
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood (1997) 1.13
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer (2012) 1.11
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia (2013) 1.11
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer (2004) 1.10
Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood (2000) 1.10
Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology (2000) 1.10
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia (2006) 1.09
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol (2003) 1.09